Platelet-rich plasma(PRP), is a concentrate of platelet-rich plasma protein derived from whole blood. The main components of it are platelets, leukocytes and fibrin. Autologous PRP treatment can avoid the immune rejection caused by exogenous growth factor and the spread of disease. Evidence of the efficacy and safety of PRP has been proven in many studies. Bronchopleural fistula (BPF) represents a challenging clinical entity characterized by abnormal communication between the bronchial tree and the pleural space. Respiratory intervention has become one of the most common treatments to fight the disease. Although the short-term occlusion effect of conventional treatment methods of respiratory intervention is relatively easy to achieve, there is great uncertainty in the long-term treatment effect, and long-term large fistulas have little chance of healing. PRP has shown significant efficacy for hyperplastic scar of skin. Correspondingly, PRP will be applied as treatment of BPF to cure fistula.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
16
PRP treatment for bronchopleural fistula
Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Cure rate for bronchopleural fistula
Proportion of patients who is no need for endotracheal intervention and with stable clinical symptoms after PRP treatment
Time frame: within 4-6 weeks after administration
the modified Medical Research Council dyspnea scale (mMRC scale)
The alleviation or aggravation of dyspnea assessed by the mMRC scale
Time frame: within 4-6 weeks after administration
COPD Assessment Test (CAT)
Change of respiratory symptoms and quality of life evaluated by the CAT
Time frame: within 4-6 weeks after administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.